Kalbitor FDA Approval History
FDA Approved: Yes (First approved December 1, 2009)
Brand name: Kalbitor
Generic name: ecallantide
Dosage form: Injection
Previous Name: DX-88
Company: Dyax Corp.
Treatment for: Angioedema
Kalbitor (ecallantide) is plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.
Development Timeline for Kalbitor
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.